The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection
暂无分享,去创建一个
G. M. Ortiz | D. Nixon | S. Bonhoeffer | M. Plana | F. García | Á. Soriano | C. Vidal | A. Cruceta | M. Arnedo | C. Gil | G. Pantaleo | T. Pumarola | T. Gallart | J. Miro | J. Gatell | S. Bonhoeffer | F. García
[1] A. Perelson,et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.
[2] Martin A. Nowak,et al. Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.
[3] A. Perelson,et al. HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.
[4] B Wise,et al. Antiretroviral therapy in adults. , 1996, Journal of the American Academy of Nurse Practitioners.
[5] S. Yerly,et al. Detection of low HIV-1 RNA levels in plasma. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[6] J. Seigneurin,et al. Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide , 1997, The Lancet.
[7] J Leibowitch,et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. , 1997, Science.
[8] G. Pantaleo. How immune-based interventions can change HIV therapy , 1997, Nature Medicine.
[9] E. Rosenberg,et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. , 1997, Science.
[10] M A Nowak,et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. , 1998, Science.
[11] Spyros A. Kalams,et al. The Critical Need for CD4 Help in Maintaining Effective Cytotoxic T Lymphocyte Responses , 1998, The Journal of experimental medicine.
[12] Felipe García,et al. Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease , 1998, The Lancet.
[13] J. Gatell,et al. Metabolic abnormalities and use of HIV-1 protease inhibitors , 1998, The Lancet.
[14] H. Clifford Lane,et al. Administration of an Anti-CD8 Monoclonal Antibody Interferes with the Clearance of Chimeric Simian/Human Immunodeficiency Virus during Primary Infections of Rhesus Macaques , 1998, Journal of Virology.
[15] J. Lisziewicz,et al. HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor , 1998, The Lancet.
[16] V. Calvez,et al. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. , 1999, AIDS.
[17] D. Richman. The challenge of immune control of immunodeficiency virus. , 1999, The Journal of clinical investigation.
[18] D. Podzamczer,et al. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study. , 1999, AIDS.
[19] M. Plana,et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. , 1999, AIDS.
[20] D. Cooper,et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study , 1999, The Lancet.
[21] S. Riddell,et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells , 1999, Nature Medicine.
[22] D. Montefiori,et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. , 1999, Science.
[23] B. Walker,et al. Levels of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T-Lymphocyte Effector and Memory Responses Decline after Suppression of Viremia with Highly Active Antiretroviral Therapy , 1999, Journal of Virology.
[24] L. Weinberger,et al. Dramatic Rise in Plasma Viremia after CD8+ T Cell Depletion in Simian Immunodeficiency Virus–infected Macaques , 1999, The Journal of experimental medicine.
[25] J. Lisziewicz,et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.
[26] A. Trkola,et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. , 1999, The Journal of clinical investigation.
[27] C. A. Macken,et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. , 1999, The New England journal of medicine.
[28] P. Harrigan,et al. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. , 1999, AIDS.
[29] J. Lisziewicz,et al. Control of HIV despite the discontinuation of antiretroviral therapy. , 1999, The New England journal of medicine.
[30] T. Kepler,et al. Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. , 1999, AIDS research and human retroviruses.
[31] D. Nixon,et al. Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy. , 2000, The Journal of infectious diseases.
[32] R H Lyles,et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. , 2000, The Journal of infectious diseases.
[33] N. Pedersen,et al. Prophylactic and Therapeutic Benefits of Short-Term 9-[2-(R)-(Phosphonomethoxy)Propyl]Adenine (PMPA) Administration to Newborn Macaques following Oral Inoculation with Simian Immunodeficiency Virus with Reduced Susceptibility to PMPA , 2000, Journal of Virology.
[34] M A Nowak,et al. The role of antigen-independent persistence of memory cytotoxic T lymphocytes. , 2000, International immunology.
[35] Felipe García,et al. Comparison of T-cell subsets' reconstitution after 12 months of highly active antiretroviral therapy initiated during early versus advanced states of HIV disease. , 2000 .
[36] P. Easterbrook,et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[37] G. M. Ortiz,et al. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. , 2000, The Journal of infectious diseases.
[38] E. Rosenberg,et al. Immune control of HIV-1 after early treatment of acute infection , 2000, Nature.
[39] J. Moore,et al. The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy. , 2000, The Journal of infectious diseases.
[40] Felipe García,et al. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection , 2000, AIDS.
[41] Alan S. Perelson,et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy , 2000, Nature Medicine.
[42] B. Clotet,et al. Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study. , 2000, Journal of acquired immune deficiency syndromes.
[43] M A Fischl,et al. Antiretroviral Therapy in Adults Updated Recommendations of the International AIDS Society–USA Panel , 2000 .